Keep up with our latest news, and connect with us on social media.


Epic Bio to Participate in the Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days

SOUTH SAN FRANCISCO, Calif. — March 29, 2023 — Epic Bio, a leading epigenome engineering company developing therapies to modulate gene expression using ultracompact, non-cutting dCas proteins, today announced that the company will participate in the Guggenheim Healthcare Talks – Genomic Medicine and Rare Disease Days, April 3-4, 2023, in New York, NY. The company will also hold meetings with investors and analysts during the event.

Amber Salzman, Ph.D., Epic Bio’s chief executive officer, is scheduled to participate in a panel on genomic medicines and rare diseases on Monday, April 3, 2023, from 1:00 – 2:00 p.m. ET.

About Epic Bio

Epic Bio is a leading epigenome engineering company, leveraging the power of CRISPR without cutting DNA. The company is using its proprietary Gene Expression Modulation System (GEMS) to develop therapies. Through the company’s library of the most compact Cas DNA-binding proteins to work on human cells, the company is developing in vivo therapies leveraging delivery via a single AAV or LNP. Epic Bio has an initial focus on Facioscapulohumeral Muscular Dystrophy (FSHD) and is conducting additional research to address Antitrypsin Deficiency (A1AD), Heterozygous Familial Hypercholesterolemia (HeFH), as well as other indications. The company is financially backed by Horizons Ventures and other leading investors. Visit for more information or follow us on Twitter and LinkedIn.

Investor Contact

Shawn M. Cox
Manager, Investor Relations, Corporate Communications
Epic Bio

Media Contact

Lisa Raffensperger
Ten Bridge Communications
(617) 903-8783

The latest from Epic

16 Nov

"The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to EPI-321 for the treatment of facioscapulohumeral muscular dystrophy (FSHD), the most common form of muscular dystrophy in adults. Read more here: "

7 Nov

"We are pleased to share that Epic Bio CEO Dr. Amber Salzman has been invited to present at the 2023 Stiefel Healthcare Conference. Read more here: "

31 Oct

"@Epicbiotech partners with @KitePharma to extend the potential application of Epic’s platform for cancer treatment. Epic’s approach is promising for in vivo medicines and may enable next-generation cell therapies #epigenetics #CellTherapy #Cancer "